Galmed Pharmaceuticals Ltd. GLMD 深 滬
已收盤 02-06 16:00:00 美东时间
0.6639
+0.069
+11.58%
華盛通- 最 高0.6779
- 今 開0.605
- 成交量 17.65万股
- 最 低 0.59
- 昨 收 0.595
- 總市值 363.77万
- 52周最高 3.50
- 市盈率 靜 --
- 換手率 3.22%
- 52周最低 0.59
- 委 比 51.36%
- 總股本 547.92万
- 歷史最高 4870.80
- 量 比 2.66
- 振 幅 14.77%
- 歷史最低 0.59
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galmed Pharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through July 28 To Regain Compliance
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company
01-31 05:15
Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July
2025-12-04 21:36
Galmed Issues CEO Letter to Shareholders
TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometa...
2025-12-01 21:30
Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.89 percent. This is a 85.71 percent increase over losses of $(2.31) per share
2025-11-26 21:34
Galmed Pharmaceuticals Reports Top-Line Results From AM-001 Phase 1 Bioavailability Study, Demonstrating Enhanced Pharmacokinetic Profile Of Aramchol Meglumine Granules
The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tabletsThe new
2025-11-18 21:44
Galmed Pharmaceuticals Q2 EPS $(0.63) Beats $(0.83) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.83) by 24.1 percent. This is a 61.82 percent increase over losses of $(1.65) per share
2025-08-28 21:36
MASH drug developers rise as FDA accepts lenient trial requirement
Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an easy-to-m...
2025-08-28 01:44
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
2025-08-19 20:01
Galmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of Quorum
The latest update is out from Galmed Pharmaceuticals ( ($GLMD) ). On August 14,...
2025-08-15 04:32
Galmed Pharma Announces Discovery Of Proprietary PD Blood-Based Biomarker Signature For Aramchol, Clinically Advanced Stearoyl-Coa Desaturase 1 Inhibitor
Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways.Validated decrease in ANP
2025-05-27 20:03
